Ionis (IONS) Q2 2026 Earnings Call Transcript
Ionis Pharmaceuticals (IONS) reported Q2 2026 total revenue of $268 million, up 56% excluding a one-time Sapablursen payment. Commercial revenue was $119 million, driven by DAWNZERA sales of $26 million (+63% QoQ). 2026 guidance: $875 million to $900 million revenue and non-GAAP operating loss of $425 million to $475 million. Cash was $2.1 billion.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated quarterly/product sales metrics, full-year revenue and operating loss guidance, and the scheduled PDUFA dates for Zilganersen and Bepirovirsen, which frame near-to-mid term catalyst risk. The CARDIO-TTRansform Phase III miss for Eplontersen is a sentiment headwind but is treated as an already-reported disappointment within the call.
Market read
Traders can use the call to reprice Ionis’ 2026 revenue trajectory, commercial launch momentum, and the probability-weighted impact of two major FDA decision dates in late 2026.
What to watch
TRYNGOLZA adoption depends on payer contracting and label interpretation (acute pancreatitis prevention), and the article’s royalty figures hinge on Biogen/WAINUA sales that may be volatile.
Background
This is Ionis’ Q2 2026 earnings call transcript, covering commercial performance, full-year guidance, cash position, and upcoming FDA decision dates.
Ticker impact
Ionis reported Q2 2026 revenue of $268M, guided 2026 revenue to $875M-$900M, and reiterated cash-flow breakeven in 2028.
Likely two-sided reaction: supportive for commercial growth and cash runway, offset by trial disappointment and ongoing binary FDA catalysts.
The article contains multiple fresh, decision-relevant datapoints (quarterly revenue, product sales, full-year guidance, and PDUFA dates) but no explicit stock-price move or new trial readout beyond the already-referenced CARDIO-TTRansform miss.
Market effects
Biotech/antisense peers may see read-through on commercial adoption of newly approved therapies and on how companies manage cash-flow targets after trial failures.
Limited direct regional spillover; primarily US-listed biotech sentiment.
Moderate, as FDA PDUFA dates and royalty streams can influence global rare-disease/antisense risk appetite.
Counterpoint
The guidance is maintained despite a Phase III miss, so investors may discount management confidence and focus on whether commercial launches can truly offset clinical and cash-flow risks.
Key entities
- companyIonis Pharmaceuticals, Inc.
Reported Q2 2026 results, reiterated 2026 guidance, and outlined upcoming FDA PDUFA dates and pipeline milestones.
- productTRYNGOLZA
Severe hypertriglyceridemia therapy with Q2 product sales of $5M and full-year sales guidance of $100M-$110M.
- productDAWNZERA
Hereditary angioedema prophylaxis therapy with Q2 product sales of $26M and full-year sales guidance of $110M-$120M.
- pipeline_programZilganersen
Alexander disease candidate with a PDUFA date of Sept. 22, 2026 under FDA priority review.
- pipeline_programBepirovirsen
Chronic hepatitis B candidate with a PDUFA date of Oct. 26, 2026.
